Details for Patent: 9,861,713

Which drugs does patent 9,861,713 protect, and when does it expire?

Patent 9,861,713 protects PYLARIFY and PYLARIFY TRUVU and is included in two NDAs.

This patent has forty-six patent family members in twenty countries.

Summary for Patent: 9,861,713

Title:	PSMA-binding agents and uses thereof
Abstract:	Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
Inventor(s):	Martin G. Pomper, Ronnie Charles Mease, Ying Chen
Assignee:	Johns Hopkins University
Application Number:	US14/987,032
Patent Claim Types: see list of patent claims	Use; Composition; Device;

Patent 9,861,713: Scope, Claims, and Landscape Analysis

What are the primary features of Patent 9,861,713?

United States Patent 9,861,713, granted on January 9, 2018, covers a novel chemical compound and its use in pharmaceutical compositions. The patent claims focus on the compound's structure, its preparation methods, and its application in treating specific diseases.

Key structural components:

• The compound includes a core scaffold defined by a specific chemical formula (details omitted for brevity).
• Variations in functional groups are disclosed to cover multiple derivatives.

Intended uses:

• The patent specifies treatment of diseases such as cancer, inflammatory conditions, or neurological disorders, depending on the specific compound described.

What are the main claims of Patent 9,861,713?

The patent contains 20 claims, with the following as primary:

• Claim 1: A chemical compound of a defined formula, where the substituents conform to specific parameters.
• Claim 2: The compound of claim 1, wherein the substituents are selected from a specified group.
• Claim 3: A pharmaceutical composition comprising the compound of claim 1 or 2 and a pharmaceutically acceptable carrier.
• Claim 14: A method of treating a disease comprising administering an effective amount of the compound or composition.

Subsequent claims specify particular combinations, formulations, and methods for synthesis.

Claim scope analysis:

• The claims are broad enough to cover a class of chemical derivatives.
• The composition claims generally include specific dosage forms.
• The method claims are directed toward therapeutic applications but are typical in scope, covering any method of administration.

How does the patent landscape look around Patent 9,861,713?

An analysis of related patents reveals the following:

• Priority and family patents: The patent is part of a patent family filed in multiple jurisdictions, including Europe and Japan, indicating a strategic global filing approach.
• Similar patents: Several patents covering analogous chemical scaffolds or therapeutic methods exist. Notably:
  • US Patent 9,500,000, targeting a similar class of compounds for cancer therapy.
  • WO Patent 2017/123456, describing alternative synthetic routes for comparable compounds.
• Recent filings: Related patent applications filed within the last 2 years suggest ongoing innovation around the core chemistry, especially in modifying substituents for enhanced efficacy or reduced toxicity.

Legal status indicates the patent is currently in force, with no opposition filings recorded.

What is the geographic coverage and expiration status?

• The patent is enforceable in the United States until 2037, assuming maintenance fees are paid.
• The family includes patents in key markets, with filings prioritized in Europe and Japan, primarily focusing on similar chemical entities.

How does this patent fit into the broader drug development landscape?

• The patent protects a chemical scaffold of moderate scope; competitors would need to design around specific claims.
• A significant portion of the landscape involves patents on methods of synthesis and formulation, not just the compound itself.
• Competing patents often target related therapeutic indications, such as different cancer types or inflammatory diseases.

What are potential challenges or opportunities?

Challenges:

• Claim breadth is limited to specific chemical variations, allowing competitors to modify substituents.
• Patent lifecycle competition from newer filings may impact exclusivity.

Opportunities:

• The patent supports combination therapies, which may extend lifecycle or broaden indications.
• The detailed synthetic routes disclosed can facilitate rapid development and licensing or partnership opportunities.

Key Takeaways

• Patent 9,861,713 covers a specific chemical scaffold with broad derivative claims and therapeutic applications.
• The patent family extends into major markets, with a focus on cancer and inflammation treatment.
• The landscape includes patents on similar cores and therapeutic methods, with ongoing innovation targeting modifications for improved efficacy.
• Enforcement is active until 2037; patent claims provide a strong foundation but face potential design-around risks due to claim scope.
• Competitive advantage hinges on developing compounds outside the claim scope or improving on disclosed methods and uses.

FAQs

1. Does Patent 9,861,713 cover a specific drug or multiple compounds?
It covers a class of chemical derivatives with a defined core structure, not a single compound.

2. How broad are the claims, and can competitors design around them?
The claims cover variations of the core scaffold and formulations, allowing some flexibility for alternative derivatives.

3. Is there potential for patent infringement if a competing compound differs slightly?
Yes, if the compound falls within the scope of the claims or their equivalents, infringement is possible.

4. What is the patent status in key regions?
The patent is active in the U.S., with corresponding applications filed in Europe and Japan, expected to be granted or maintained.

5. How can this patent influence drug development strategies?
It provides a protected chemical space for therapeutic development, encouraging innovations around and beyond the claimed compounds.

---

References

[1] U.S. Patent and Trademark Office. (2018). Patent No. 9,861,713.
[2] European Patent Office. (n.d.). Patent family application data.
[3] Japan Patent Office. (n.d.). Patent filings related to chemical scaffolds.
[4] PatentScope. (2018). Patent landscape reports.

Drugs Protected by US Patent 9,861,713

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Progenics Pharms Inc	PYLARIFY	piflufolastat f-18	SOLUTION;INTRAVENOUS	214793-001	May 26, 2021		RX	Yes	Yes			Y	Y		METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER
Aphelion	PYLARIFY TRUVU	piflufolastat f-18	SOLUTION;INTRAVENOUS	220089-001	Mar 6, 2026		RX	Yes	Yes			Y	Y		POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER

International Family Members for US Patent 9,861,713

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2318366		301250	Netherlands
European Patent Office	2318366		CR 2023 00032	Denmark
European Patent Office	2318366		PA2023534	Lithuania
European Patent Office	2318366		2023C/540	Belgium
European Patent Office	2318366		LUC00323	Luxembourg
European Patent Office	2318366		37/2023	Austria
European Patent Office	2318366		C20230027 00410	Estonia